Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
1
|
pubmed:dateCreated |
1995-2-21
|
pubmed:abstractText |
We studied the effects of the enantiomers of the dihydropyridine derivative, 4-(2,3 methylenedioxyphenyl)-1,4-dihydro-2,6-dimethyl-3 carboxyethyl-5-carboxymethyl-pyridine (oxodipine), on voltage-dependent Ca2+ channels of rat portal vein myocytes by combining electrophysiological techniques and binding studies. (+)- and (-)-oxodipine depressed the L-type Ca2+ current in a concentration-dependent manner, with similar IC50 values (around 10 nM) but had no appreciable effect on the intracellular Ca2+ stores. The steady-state inactivation curve for the Ca2+ current was shifted along the voltage axis to negative membrane potentials indicating that the block of the Ca2+ current by oxodipine enantiomers increased with depolarization. The voltage-dependent inhibitory property of oxodipine was related to an increase in [3H](+)-4-(benzo-2-oxa-1,3-diazol-4-yl)-1,4-dihydro-2,6-dimethy lpy ridine- 3,5-dicarboxylic acid 3-isopropyl, 5-methyl ester (isradipine) binding affinity without change in binding capacity. In normally polarized intact strips, interactions of (+)- and (-)-oxodipine with [3H](+)-isradipine binding indicated a stimulation of the radioligand binding at low concentrations of (-)-oxodipine while the (+) enantiomer seemed to act as a competitive ligand. Depolarization of intact strips with 135 mM K(+)-solutions increased the apparent affinity of the enantiomers of oxodipine, and abolished the stimulating effect of (-)-oxodipine on the binding of [3H](+)-isradipine. Inhibition of Ca2+ current was increased in the simultaneous presence of 1 nM of (+)- and (-)-oxodipine when compared to the inhibitions induced by 2 nM of each enantiomer.(ABSTRACT TRUNCATED AT 250 WORDS)
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Sep
|
pubmed:issn |
0014-2999
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:day |
15
|
pubmed:volume |
269
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
105-13
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:7828652-Animals,
pubmed-meshheading:7828652-Binding, Competitive,
pubmed-meshheading:7828652-Calcium Channel Blockers,
pubmed-meshheading:7828652-Computer Simulation,
pubmed-meshheading:7828652-Dihydropyridines,
pubmed-meshheading:7828652-Dose-Response Relationship, Drug,
pubmed-meshheading:7828652-Electrophysiology,
pubmed-meshheading:7828652-Isradipine,
pubmed-meshheading:7828652-Muscle, Smooth, Vascular,
pubmed-meshheading:7828652-Patch-Clamp Techniques,
pubmed-meshheading:7828652-Portal Vein,
pubmed-meshheading:7828652-Radioligand Assay,
pubmed-meshheading:7828652-Rats,
pubmed-meshheading:7828652-Stereoisomerism
|
pubmed:year |
1994
|
pubmed:articleTitle |
Inhibition of L-type Ca2+ channels in portal vein myocytes by the enantiomers of oxodipine.
|
pubmed:affiliation |
Laboratoire de Physiologie Cellulaire et Pharmacologie Moléculaire, URA CNRS 1489, Université de Bordeaux II, France.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|